6/26/2009

A European advisory panel issued a positive opinion on Bristol-Myers Squibb and AstraZeneca's Type 2 diabetes treatment Onglyza. The recommendation echoes an FDA panel's endorsement and could boost the chance of approval by the European Commission.

Related Summaries